Spark Therapeutics Aktie
Finanztrends
Deine Einschätzung
Was spricht für und gegen Spark Therapeutics in den nächsten Jahren?
Pro
?
U****************
?
M****
?
L*********** I********** f** d** n******* J****
Kontra
?
A****************
?
W******* i* V********
?
M************
Sag uns deine Meinung, um die 'Wisdom of the Crowds' zu nutzen
Rendite von Spark Therapeutics im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Spark Therapeutics | - | - | - | - | - | - | - |
| Ligand Pharmaceuticals | -3,82 % | -0,78 % | -9,29 % | 117,09 % | 53,01 % | 319,83 % | 171,19 % |
| United Therapeutics | -0,58 % | 3,81 % | -5,57 % | 81,46 % | 9,06 % | 115,54 % | 156,04 % |
| Ionis Pharmaceuticals Inc. | 1,99 % | 8,77 % | -35,38 % | 39,93 % | -28,12 % | 37,45 % | 47,99 % |
Kommentare
News
Omada Health Q2 Earnings Call Highlights
Omada Health (NASDAQ:OMDA) reported record second-quarter results for 2026, citing broad-based growth across its cardiometabolic programs, expanding channel partnerships and lower costs to serve
Cirrus Logic Q1 Earnings Call Highlights
Key Points
- Interested in Cirrus Logic, Inc.? Here are five stocks we like better.
- Record quarterly performance: Cirrus Logic reported fiscal Q1 revenue of $460 million, up 13% year over year
Match Group Q2 Earnings Call Highlights
Key Points
- Interested in Match Group Inc.? Here are five stocks we like better.
- Match Group reported mixed Q2 results: Revenue fell 1% year over year to $853 million, while adjusted EBITDA